| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2121973 | European Journal of Cancer | 2014 | 9 Pages |
Abstract
Median overall survival in this selected patient cohort is 45.3Â months. Despite the lack of prospective randomised controlled trials, PM is a reasonable treatment strategy in selected patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
S. Schur, K. Hoetzenecker, W. Lamm, W.J. Koestler, G. Lang, G. Amann, P. Funovics, E. Nemecek, I. Noebauer, R. Windhager, W. Klepetko, T. Brodowicz,